How to appeal a CareFirst BCBS growth hormone replacement therapy denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

CareFirst BCBS-specific note: BCBS licensee for Maryland, DC, and northern Virginia (~3.5M members). Operates as non-profit. Appeals jurisdiction depends on policy issue location — MIA (MD), DISB (DC), or SCC Bureau of Insurance (VA). CVS Caremark is the PBM.

What CareFirst BCBS's policy requires for growth hormone replacement therapy

Cited policy: BCBS Ngenla (Somatrogon-ghla) Once-Weekly GH PA

Pediatric GHD age >=3 yr per FDA Jun 27 2023 label. Two provocative GH stim tests with peak GH <10 ng/mL (BMI-adjusted). IGF-1 SDS low. Pituitary MRI. Endocrinologist Rx. Step-therapy: prior 6-12 mo daily somatropin trial typically required unless contraindicated or adherence-limited. Reauth at 12 mo with HV + IGF-1 response.

How CareFirst BCBS denies growth hormone replacement therapy — and how to counter it

Where CareFirst BCBS pushes back: 1) Weekly GH experimental / investigational; 2) Cheaper daily somatropin available — clinically equivalent; 3) Brand-on-formulary forced switch (must use Skytrofa / Sogroya).

Counter-arguments that hold up: Ngenla FDA-approved Jun 27 2023 — Deal JCEM 2022 Phase 3 (n=224 treatment-naive peds GHD) non-inferior AHV vs daily somatropin at 12 mo. PES 2022 statement supports weekly GH options. Adherence with daily injections documented poor — KIGS registry. Document specific daily-GH adherence failure / device intolerance / caregiver burden / school + sports avoidance. Ngenla device platform (single-use prefilled pen, room-temp stable 4 days) differs materially from Skytrofa (TransCon prodrug Auto-Injector) and Sogroya (FlexTouch pen) — patient-fit selection is medically necessary, not interchangeable. Cite Social Security Act 1927(d)(4) brand-medical-necessity.

What CareFirst BCBS typically denies for growth hormone replacement therapy

Across CareFirst BCBS's commercial and Medicare books, denials cluster around a small number of patterns. For growth hormone replacement therapy, expect:

• DC/MD/VA cross-jurisdiction issues
• Step therapy on specialty drugs via CVS Caremark
• Behavioral health network adequacy
• BlueChoice HMO referral denials

Treatments most often denied in this category

These are the growth hormone replacement therapy treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Norditropin (daily)
• Genotropin (daily)
• Humatrope (daily)
• Saizen (daily)
• Omnitrope (biosimilar daily)
• Nutropin AQ (daily)

How to submit the appeal to CareFirst BCBS

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document CareFirst BCBS cited in the denial.
3. File the appeal through CareFirst BCBS's portal (members: https://member.carefirst.com ; providers: https://provider.carefirst.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MD, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See CareFirst BCBS's prior-authorization criteria by drug: CareFirst BCBS PA criteria on ApprovalHelp.